(REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read ...

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

Regeneron's purchase is still subject to court ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) operates within the biotechnology sector and is listed on Biggest Companies on Nasdaq ...

Throughout the last three months, 16 analysts have evaluated Regeneron Pharmaceuticals (NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Source: Regeneron Pharmaceuticals, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

In children aged 8 to 11 years, PRALUENT should be given by a caregiver. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming ...